Wearable injectors are drug delivery devices that allow the injection of a large volume of dosage via subcutaneous route, which offers advantages to patients, clinicians, and drug developers. In these devices, a needle is inserted after the injector is attached. The drug is released with the press of a button after which the needle automatically retracts and locks itself. The patient is notified about the process with audio or visual signals.
Off-Body Wearable Injectors to Rise in Popularity
Wearable injectors can be broadly classified into on-body and off-body devices. There will be a higher consumer inclination toward on-body injectors owing to the convenience offered by them. They are mostly water resistant and comfortable to wear on the skin. They offer several benefits such as flexible dosing, automated warming of refrigerated drug, and decreased healthcare costs. Additionally, they ensure easy application and do not hamper daily lifestyle of patients. Rising awareness regarding their benefit will stir up the adoption.
Several companies are also investing sizeable sums in the development of advanced on-body wearable injectors, which is contributing to the growth of the segment. For instance, Enable Injections offers a disposable on-body injector to deliver a high volume of high viscosity biological products /drugs to the subcutaneous tissue.
Off-body wearable injectors, on the other hand, are poised to witness healthy growth in coming years as they eliminate risks such as adhesive fitting issues, painful removal of devices, and skin irritation or sensitivity.
Market Insights
A report by Grand View Research, Inc. finds that the global wearable injectors market is anticipated to amount to USD 11.3 billion by 2025. Growing global geriatric population is one of the key growth stimulants of the market. The World Health Organization (WHO) estimates that the global population aged 60 years and above will increase to more than 2.0 billion by the end of 2050. Since aged people are more prone to chronic diseases, this factor is leading to increased incidence of diabetes, cancer, neurological disorders, and other chronic diseases, which can also work in favor of the market.
North America will represent a significant share in the market over the forecast horizon (2017 to 2025). Domicile of a wide base of key players coupled with presence of an advanced healthcare infrastructure is supplementing the growth of the regional market. Some of the prominent companies in the market are Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; SteadyMed Therapeutics, Inc.; West Pharmaceutical Services, Inc.; and Insulet Corporation.
Read more at:
Read more at:
No comments:
Post a Comment